Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (7238)	8/27/2017 9:41:59 AM
From: nigel bates	1 Recommendation Recommended By scaram(o)uche Read Replies (2) \| Respond to of 7424

Some medics getting quite excited about the prospects for canakinumab... telegraph.co.uk (& the XOMA royalties aren't completely negligible.) XOMA is also eligible to receive low-single-digit royalties on canakinumab sales in cardiovascular indications rising to mid-single-digit royalties under certain circumstances.

To: Jibacoa who wrote (7238)	9/5/2017 1:50:37 PM
From: Jibacoa	Respond to of 7424

XOMA has continued its Up-Trend. <g> It is up another 31.40% today at $14.85 and it looks overbought. <g> However, it is still below the $9300 at which Rick said he sold his shares.<g> Although the Finviz Charts, only go back to 2009 when the monthly high reportedly was $400 <g> https://elite.finviz.com/chart.ashx?t=XOMA&ty=c&ta=0&p=m&s=l&rev=1504633531837 And the yearly charts in Stockcharts.com are not available as it seems they are having some prblems with their website today. <g> Will have to just keep a close watch on it.<g> Bernard